SPINE2-COMPLEXES - From Receptor to Gene: structures of complexes from signalling pathways linking immunology, neurobiology and cancer (FP6-LIFESCIHEALTH) (2006-07-01 - 2009-12-31) (»add to infobox)

David Ian STUART, Joel SUSSMAN, Stephen CUSACK, Dino MORAS, Gunter SCHNEIDER, Keith Sanderson WILSON, Rolf BOELENS, Titia K. SIXMA, Ivano BERTINI, Sine LARSEN, Udo HEINEMANN, Miquel COLL, Yves BOURNE, Herman VAN TILBEURGH, Beata VERTESSY, Jan DOHNALEK, Maria Arménia CARRONDO, Renos SAVVA

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain), WEIZMANN INSTITUTE OF SCIENCE (NoRegion - NoRegion) (Israel), EUROPAISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE - EMBL (DE125 - Heidelberg, Stadtkreis) (Germany), CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE (FR421 - Bas-Rhin) (France), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), UNIVERSITY OF YORK (UKE21 - York) (Great Britain), BIOCLEAR BV (NL113 - Overig Groningen) (Netherlands), HET NEDERLANDS KANKER INSTITUUT / ANTONI VAN LEEUWENHOEK HOSPITAL (NL326 - Groot-Amsterdam) (Netherlands), CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLOPROTEINE PARAMAGNETICHE (ITE14 - Firenze) (Italy), INSTALLATION EUROPEENNE DE RAYONNEMENT SYNCHROTRON (FR714 - Isère) (France), MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE300 - Berlin) (Germany), CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES300 - Madrid) (Spain), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (France), UNIVERSITE PARIS-SUD (FR104 - Essonne) (France), MAGYAR TUDOMANYOS AKADEMIA (HU101 - Budapest) (Hungary), AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE (CZ010 - Hlavni mesto Praha) (Czech Republic), INSTITUTO DE TECNOLOGIA QUIMICA E BIOLOGICA - UNIVERSIDADE NOVA DE LISBOA (PT171 - Grande Lisboa) (Portugal), DOMAINEX LIMITED (UKI11 - Inner London - West) (Great Britain)

SPINE2-COMPLEXES (S2C) builds on SPINE successes (in establishing infrastructure and activity in HTP structural biology across Europe) to attack two of the central objectives of Structural Biology. Firstly, S2C will focus on systems of demonstrated biomedical relevance, almost entirely human proteins (plus some viral mimics). Secondly it will address the functional form of these proteins, complexes, interlinked in human signalling pathways of importance for human health. The S2C team is built upon a core of SPINE laboratories, selected on the basis of their enthusiasm to sign up to the concept of sharing work and pooling protein reagents within the Partnership to accelerate progress through cooperation. The new Partners include excellent young group leaders from the New Member States. Despite dramatic technological advances in HTP protein production there is an urgent need to develop specific technologies appropriate to S2C not covered by other FP6 grants (eg synchrotron technology is largely addressed by BIOXHIT). Major technology developments will therefore be in protein production, especially HTP methods for eukaryotic expression, including co-expression, through refolding, to library based methods. The human signaling pathways targeted are i) ubiquitination and de-ubiquitination ii) cell cycle and apoptosis iii) synaptogenesis and neuronal signalling iv) kinases and phosphatases involved in signalling and regulation v) transcriptional receptors and regulation vi) innate and acquired immune receptors and inflammation and vii) viral subversion of cellular signalling and immune modulation. These cellular processes frequently involve the same components and pathways, enhancing opportunities for interpartner synergies. All Partners have signed up to joint target activity with at least one other Partner. Since S2C builds on SPINE we will be able to implement a transparent and effective management system, minimising the start-up time.

PERSONS (18/18)

RELATED NAVIGATION AREA(S) (3/3)